                           
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi,
L., ... Omega-3 Treatment Trialists’ Collaboration (2018). Associations of
Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks:
Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiology.
https://doi.org/10.1001/jamacardio.2017.5205
Peer reviewed version
Link to published version (if available):
10.1001/jamacardio.2017.5205
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via AMA at https://jamanetwork.com/journals/jamacardiology/fullarticle/2670752 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  
 
Omega-3 fatty acids and risk of cardiovascular disease:  
meta-analysis of 10 trials involving 77,900 individuals 
 
Theingi Aung FRCP1,2, Jim Halsey BSc1, Daan Kromhout PhD3,  
Hertzel C Gerstein MD4, Roberto Marchioli MD5,6, Luigi Tavazzi MD7,  
Johanna M Geleijnse PhD3, Bernhard Rauch MD8, Andrew Ness FFPHM9,  
Pilar Galan MD10, Emily Y Chew MD11, Jackie Bosch PhD4, Rory Collins FRCP1, 
Sarah Lewington DPhil1, Jane Armitage FRCP1, Robert Clarke FRCP1 for the 
Omega-3 Treatment Trialists’ Collaboration. 
 
1 Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), and MRC Population 
Health Research Unit, Nuffield Department of Population Health, University of Oxford, 
Oxford, UK; 
2 Department of Endocrinology, Royal Berkshire Hospital, Reading, UK 
3 Department of Human Nutrition, Wageningen University, Wageningen, Netherlands;  
4 Department of Medicine and Population Health Research Institute, McMaster University 
and Hamilton Health Sciences, Hamilton, Ontario, Canada;  
5 Cardiovascular Renal Metabolic (CVRM) Therapeutic Area, Medical Strategy and Science, 
Therapeutic Science and Strategy Unit (TSSU), Quintiles, Milan, Italy;  
6 Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche 
Mario Negri, Milan, Italy; 
7 Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, 
Cotignola, Italy; 
8Institut für Herzinfarktforschung Ludwigshafen (IHF), Ludwigshafen, Germany; 
9 National Institute for Health Research Biomedical Research Unit in Nutrition, Diet and 
Lifestyle at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, 
Bristol, UK; 
10Sorbonne Paris Cité Epidemiology and Biostatistics Research Center (CRESS), Nutritional 
Epidemiology Research Team (EREN), Inserm U1153, Inra U1125, Cnam, Paris 13 
University, Bobigny, France; 
11National Eye Institute, National Institutes of Health, Building 10, CRC Room 3-2531, 10 
Center Drive, MSC 1204, Bethesda, MD 20892-1204, USA. 
 
 
 
Please confirm that the details for you and your affiliation are correct and 
return the form to me (robert.clarke@ndph.ox.ac.uk). 
Yes
 
No  
 
If no, please correct or amend this page using track changes before returning 
it to robert.clarke@ndph.ox.ac.uk. 
 
 
 
 
Name:  ……………………………………….. 
 
 
  
 
The following are Members of the OMEGA-3 Treatment Trialists’ 
Collaboration 
 
 
Secretariat: Theingi Aung FRCP, Jim Halsey BSc, Rory Collins FRCP, Sarah 
Lewington DPhil, Jane Armitage FRCP, Robert Clarke FRCP. Nuffield Department of 
Population Health, University of Oxford, Oxford, UK 
 
Age-Related Eye Disease Study 2 (AREDS-2): Denise E Bonds MD MPH, Molly 
Harrington MS, Emily Y Chew MD. National Eye Institute, National Institutes of Health, 
Bethesda, MD, USA 
 
Supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids trial 
(SU.FOL.OM3): Pilar Galan MD, Serge Hercberg MD. Sorbonne Paris Cité 
Epidemiology and Biostatistics Research Center (CRESS), Inserm U1153, Paris, 
France 
 
ALPHA OMEGA: Daan Kromhout PhD, Eric J Giltray MD; Johanna M Geleijnse PhD. 
Wageningen University, Wageningen, Netherlands  
 
OMEGA: Bernard Rauch MD. Institut für Herzinfarktforschung Ludwigshafen (IHF), 
Ludwigshafen, Germany 
 
Risk and Prevention Study (R&P): Roberto Marchioli MD; Gianni Tognoni MD; Maria 
Carla Roncaglioni MD. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, 
Italy 
 
GISSI Heart Failure Trial (GISSI-HF): Luigi Tavazzi MD, Aldo P Maggioni MD; Roberto 
Marchioli MD; Dr Donata Lucci BS. IRCCS-Istituto di Ricerche Farmacologiche Mario 
Negri, Milan, Italy  
 
Outcome Reduction With Initial Glargine Intervention (ORIGIN): Jackie Bosch MSc; 
Hertzel Gerstein MD. McMaster University and Hamilton Health Sciences, Hamilton, 
Ontario, Canada  
 
GISSI-Prevenzione (GISSI-P): Roberto Marchioli MD; Aldo P Maggioni MD; Gianni 
Tognoni MD. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy 
 
Diet and Reinfarction Trial (DART): Andrew Ness MRCP. University of Bristol, Bristol, 
UK 
 
 
Please verify that the full names, degrees and affiliations for collaborators in 
your trial listed above are correct and return the form to me. 
Yes  
No  
 
If no, please correct or amend this page using track changes before returning 
it to robert.clarke@ndph.ox.ac.uk. 
 
